Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD ‐4 substudy
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aim: To conduct a substudy, using 24‐hour continuous glucose monitoring ( CGM ), of the AWARD ‐4 trial, which was designed to compare insulin + glucagon‐like peptide‐1 receptor agonist treatment with an insulin‐only regimen. Methods: The AWARD ‐4 trial randomized 884 conventional insulin regimen‐treated patients to dulaglutide 1.5 mg, dulaglutide 0.75 mg and glargine, all in combination with prandial insulin lispro. The CGM substudy included 144 patients inserted with a Medtronic CGMS iPro CGM device to enable 3‐day glucose monitoring. CGM sessions were completed at weeks 0, 13, 26 and 52. CGM measures included mean 24‐hour glucose, percentage time in target glucose ranges, hyper‐ and hypoglycaemia and glucose variability. The primary objective was treatment comparison for percentage time spent with CGM glucose values in the 3.9‐7.8 mmol/ L range after 26 weeks. Results: At week 26, mean CGM values decreased in all treatment groups (change from baseline −2.8 ± 0.3, −2.4 ± 0.3 and −2.5 ± 0.3 mmol/ L for dulaglutide 1.5 mg, dulaglutide 0.75 mg and glargine, respectively); between‐group differences were not statistically significant. Treatment groups were similar for percentage time in the 3.9‐7.8 mmol/ L range. Percentage time in the 3.9‐10.0 mmol/L range was greater for dulaglutide 1.5 mg than for glargine (p < 0.05). Dulaglutide and glargine were associated with decreased glucose variability for all CGM variability indices. The overall within‐patient standard deviation (s.d.) was significantly reduced with dulaglutide 1.5 mg versus glargine (p < 0.05). At week 52, there were no significant differences among the groups with regard to measures of normoglycaemia or near‐normoglycaemia and for the overall within‐patient s.d. Treatment with glargine was associated with greater increases in percentage time spent with glucose values ≤3.9 mmol/ L , with statistically significant differences between the groups at 52 weeks (p < 0.05). Conclusions: In combination with prandial lispro, treatment with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycaemic range, but dulaglutide provided an improved balance between the proportion of values within the near‐normoglycaemia range and values within the hypoglycaemic range.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010
Stark Casagrande, S., Fradkin, J. E., Saydah, S. H., Rust, K. F., & Cowie, C. C. (2013) · Diabetes Care · doi:10.2337/dc12-2258 · Cited by 719 · cited 1×
“When monotherapy with oral antihyperglycaemic medication (OAM) or OAM combination therapy becomes insufficient for achieving glucose targets in patients with type 2 diabetes (T2D), addition of insulin is recommended.(1,2) Insulin therapy enables a significant proportion of patients to attain their glucose targets, but…”
BackgroundBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · cited 1×
“In two additional studies that included basal-bolus insulin regimens as the active comparators, the basal insulin–GLP-1 receptor agonist combination was non-inferior with respect to the effect on glycated haemoglobin (HbA1c) and resulted in lower hypoglycaemia rates and weight loss compared with basal-bolus insulin.(6…”
ResultCox, D. J., Kovatchev, B. P., Julian, D. M., Gonder-Frederick, L. A., Polonsky, W. H., Schlundt, D. G., & Clarke, W. L. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989471 · Cited by 137
Cited by
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
Dandona, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0372 · Cited by 67
“Finally, as part of the AWARD-4 trial, the effects of dulaglutide versus insulin glargine on glycemic fluctuations were assessed.(57) A subgroup of 144 patients taking either once-weekly dulaglutide (1.”
BackgroundSignificance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
Metadata
- Authors
- Jendle, J., Testa, M. A., Martin, S., Jiang, H., & Milicevic, Z.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-07-22
- Volume
- 18
- Issue
- 10
- Pages
- 999-1005
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2409477315
- Cited by
- 47
- References
- 7
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD ‐4 substudy. https://app.cochat.ai/papers/10.1111/dom.12705
- The paper
- Jendle, J., Testa, M. A., Martin, S., Jiang, H., & Milicevic, Z. (2016). Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD ‐4 substudy. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12705
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.